ChemoCentryx, Inc. Advances a New Generation CCR9 Inhibitor, CCX507, Into Clinical Development

Published: Jan 07, 2013

MOUNTAIN VIEW, Calif., Jan. 7, 2013 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today the initiation of a Phase I clinical trial for CCX507, the Company's novel, wholly-owned inhibitor of the chemokine receptor known as CCR9. The double-blind, placebo-controlled study will evaluate the safety, tolerability and pharmacokinetics of CCX507 in healthy adult subjects.

Back to news